Oversubscribed Retail Offer
Futura Medical plc has announced that its Retail Offer was significantly oversubscribed, leading to a conditional raise of £200,000 through the issue of 100,000,000 new Ordinary Shares. This brings the total conditional funds raised to approximately £1.8 million, including the Firm Placing, Conditional Placing, and Conditional Subscription. Admission of the Retail Offer shares to AIM is contingent on shareholder approval at a general meeting on September 23, 2026, with initial admission of Firm Placing shares expected on September 9, 2026, and subsequent admission of all new shares on September 25, 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Unless otherwise defined, definitions contained in this announcement have the same meanings as set out in the Company's announcements dated 3 September 2026.
Futura Medical plc
("Futura" or the "Company")
Oversubscribed Retail Offer
Futura Medical plc (AIM: FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that the Retail Offer on the BookBuild platform, which closed at 4:30 p.m. on Friday, 4 September 2026, was significantly oversubscribed.
Consequently, the Company, after consultation with its advisers, has upscaled the Retail Offer from the intended £150,000 and instead conditionally raised £200,000, before expenses, through the issue of 100,000,000 new Ordinary Shares of 0.2p each (the "Retail Offer Shares"). with allocations scaled back proportionately, taking into account both applicants' existing shareholdings and the number of Retail Offer Shares applied for. As a result, the Company has conditionally raised a total of approximately £1.8 million, before expenses, pursuant to the Firm Placing, Conditional Placing, Conditional Subscription and Retail Offer.
General Meeting, Admission and Total Voting Rights
As referenced in the announcement of 3 September 2026 and the Circular dated 4 September 2026, admission of the Retail Offer shares to trading on AIM is conditional upon the passing of the Equity Funding Resolutions to be tabled at a general meeting of the Company, scheduled for 10:00 a.m. on 23 September 2026. Immediately following admission of the Firm Placing Shares to trading on AIM (the "Initial Admission"), the Company will have 639,460,530 ordinary shares of £0.002 each in issue. An announcement confirming total voting rights following issue of the Conditional Placing Shares, Conditional Subscription Shares and the Retail Offer Shares (the "Subsequent Admission"), will be released by the Company in due course. It is expected that Initial Admission will become effective and dealings in the Firm Placing Shares will commence on AIM at 8.00 a.m. on 9 September 2026 and that Subsequent Admission will become effective and dealings commence on AIM at 8.00 a.m. on 25 September 2026.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.